Navigation Links
Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Date:5/20/2009

June 1994 to July 1998, Mr. Bentsur worked as an investment banker in NYC, most of this period at ING Barings Furman Selz. Mr. Bentsur holds a BA in Economics and Business Administration with distinction from the Hebrew University of Jerusalem, Israel and an MBA, Magna Cum Laude, from New York University's Stern Graduate School of Business.

The terms of Mr. Bentsur's employment are being finalized and will be set forth in an employment agreement with the Company. As an inducement to his employment, the Company has granted Mr. Bentsur options to purchase 600,000 shares of Company common stock, at an exercise price equal to the fair market value of the stock as of May 20, 2009, the date of grant. The options will vest in equal annual installments over a four-year period or upon an earlier change in control of the Company.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM)(ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)...   Synthetic Biologics, Inc. (NYSE MKT: ... and drug programs targeting specific pathogens that cause ... the Company,s Investor Day in New ... syndrome (IBS) program, including its novel, oral product ... the keynote presentation, Mark Pimentel , MD, ...
(Date:9/16/2014)... LOUISVILLE, Ky. , Sept. 16, 2014 /PRNewswire/ ... laboratory technologies and products to hospitals, physician office ... announce that, effective October 1, 2014, it will ... in specified hospital market segments and as a ... in the 48 contiguous United States ...
(Date:9/16/2014)... In preparation for VARTECH 2014, 2FA, Inc., ... focused on authentication and SSO announced today that their ... generate a OTP through the presentation of an RFID ... RFID authentication, 2FA,s solutions have leveraged the existence of ... RFID authentication is broadly deployed in healthcare and other ...
(Date:9/16/2014)... 16, 2014 RENU 28, the world's first ... available for purchase in Australia and New Zealand in ... beginning September 16th. The tour will make stops in Brisbane ... on the 18th, Sydney on the 20th, and Melbourne on ... and New Zealand and to educate people about the new ...
Breaking Biology Technology:Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 32FA, Inc. Announces RFID-based One-Time Password (OTP) Authentication 2Global Wellness Company Hosts ASEA Australia Tour September 16-22 2
... , SANTA CLARA, Calif. , Jan. 28 Coherent, Inc. (Nasdaq: COHR ), a world leader in providing ... , FINANCIAL HIGHLIGHTS , , , , , ... Three Months Ended, ... ------------------, GAAP Results ...
... , MADRID , Jan. 28 The ... category goes to physicist and chemist Richard N. Zare , ... , of the University of Maryland , for their independent, ... unraveled secrets of nature,s building blocks and the underlying interactions between ...
... ... Webster Cavenee, Ph.D., and Frank Furnari, Ph.D., along with their team at ... Diego School of Medicine, have recently discovered one way that brain tumors ... stop tumor growth. This breakthrough discovery revealed a new cellular mechanism ...
Cached Biology Technology:Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 2Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 3Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 4Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 5Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 6Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 7Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 8Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 9Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 10Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 11Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance 12Zare and Fisher Win the BBVA Foundation Frontiers of Knowledge Award in Basic Sciences for Rendering Molecules Visible and Analyzing Their Collective Behavior 2Zare and Fisher Win the BBVA Foundation Frontiers of Knowledge Award in Basic Sciences for Rendering Molecules Visible and Analyzing Their Collective Behavior 3Zare and Fisher Win the BBVA Foundation Frontiers of Knowledge Award in Basic Sciences for Rendering Molecules Visible and Analyzing Their Collective Behavior 4Zare and Fisher Win the BBVA Foundation Frontiers of Knowledge Award in Basic Sciences for Rendering Molecules Visible and Analyzing Their Collective Behavior 5Zare and Fisher Win the BBVA Foundation Frontiers of Knowledge Award in Basic Sciences for Rendering Molecules Visible and Analyzing Their Collective Behavior 6Zare and Fisher Win the BBVA Foundation Frontiers of Knowledge Award in Basic Sciences for Rendering Molecules Visible and Analyzing Their Collective Behavior 7NFCR Scientists Discover Brain Tumor's “Escape Path” 2NFCR Scientists Discover Brain Tumor's “Escape Path” 3
(Date:9/15/2014)... allow us to better understand how the fish ... and provide the type of environmental data to ... siting of protected areas," said Paula Whitfield, a ... Ocean Science (NCCOS) and lead author of the ... the temperate-tropical transition zone, where historically, both temperate ...
(Date:9/15/2014)... 500 million years after it formed may have been ... continents and active crustal plates. , This alternate view ... gained substantial new support from the first detailed comparison ... years ago with those formed contemporaneously in Iceland, which ... early Earth. , The study was conducted by a ...
(Date:9/15/2014)... hearing and cognitive function may play roles in one,s ... rhythm, pitch, timbre, tone durations, and formal structure in ... article explain that extremes in musical aptitude (extreme capacity/no ... of individuals having moderate aptitude. , "This is a ... underlying genes, and it is influenced to varying degrees ...
Breaking Biology News(10 mins):Study finds warming Atlantic temperatures could increase range of invasive species 2Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3
... ovarian ,chocolate, cysts for the brown liquid they contain, ... common, which can cause ongoing pain and complications. A ... and effective remedy the oral contraceptive pill (OCP). ... Reilly from Auckland, New Zealand, highlight a trial published ...
... AUGUSTA, Ga. - New drugs that are helping fight ... cardiovascular disease, Medical College of Georgia researchers said. Cancer ... as a cause. Heat shock protein 90 inhibitors as a ... director of MCG,s Vascular Biology Center. "I think hsp90 ...
... use of Chinese wolfberries to improve vision deficiencies that are ... assistant professor of human nutrition, is studying wolfberries and their ... that the fruit can lower the oxidative stress that the ... would not say that wolfberries are a medicine, but they ...
Cached Biology News:New cancer therapy may fight cardiovascular disease 2Study uses Chinese wolfberries to improve vision imperfections caused by type-2 diabetes 2Study uses Chinese wolfberries to improve vision imperfections caused by type-2 diabetes 3
... custom siRNA service provides the premium quality ... research. Custom siRNAs can be readily ordered ... target sequence, or by providing the sense ... Ambion's Silencer Validated and Silencer Pre-designed siRNAs, ...
... Ambion's custom siRNA service provides the premium ... silencing research. Custom siRNAs can be readily ... base target sequence, or by providing the ... out Ambion's Silencer Validated and ...
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Biology Products: